{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:14:58Z","timestamp":1776770098397,"version":"3.51.2"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007210","name":"Varian Medical Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009925","name":"Villadsen Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004196","name":"Odense Universitetshospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.radonc.2025.110748","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T11:54:40Z","timestamp":1737978880000},"page":"110748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["1-year efficacy results after MR-guided risk-adapted stereotactic radiotherapy of infra-diaphragmatic oligometastases in a multicenter phase II trial"],"prefix":"10.1016","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1069-5999","authenticated-orcid":false,"given":"Mette","family":"van Overeem Felter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0761-8028","authenticated-orcid":false,"given":"Pia Krause","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8288-162X","authenticated-orcid":false,"given":"Mirjana","family":"Josipovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5384-5988","authenticated-orcid":false,"given":"Susanne N\u00f8rring","family":"Bekke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-2696","authenticated-orcid":false,"given":"Uffe","family":"Bernchou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6851-2086","authenticated-orcid":false,"given":"Eva","family":"Serup-Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parag","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8371-2852","authenticated-orcid":false,"given":"Joshua","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poul","family":"Geertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0686-1421","authenticated-orcid":false,"given":"Claus P.","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7612-3906","authenticated-orcid":false,"given":"Kapser","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan R.","family":"Vogelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob Fink","family":"Tops\u00f8e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Kiil","family":"Berthelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"P\u00f8hl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6705-1561","authenticated-orcid":false,"given":"Tine","family":"Schytte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gitte Fredberg","family":"Persson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110748_b0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative Radiotherapy for Limited Metastatic Non\u2013Small-Cell Lung Cancer","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0010","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12885-017-3455-6","article-title":"A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)","volume":"17","author":"Radwan","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2025.110748_b0015","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0020","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.110748_b0030","article-title":"Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC","author":"Wang","year":"2022","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.radonc.2025.110748_b0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12885-018-4191-2","article-title":"The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases","volume":"18","author":"Andratschke","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2025.110748_b0045","article-title":"Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis","volume":"13","author":"Hong","year":"2018","journal-title":"PLoS One1"},{"key":"10.1016\/j.radonc.2025.110748_b0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.4394","article-title":"Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial","author":"Olson","year":"2022","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0055","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/j.ijrobp.2012.06.005","article-title":"Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for abdominopelvic malignancies","volume":"84","author":"Bae","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110748_b0060","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ijrobp.2022.07.027","article-title":"MRI-guided Radiotherapy (MRgRT) for Treatment of Oligometastases: Review of Clinical Applications and Challenges","volume":"114","author":"Chetty","year":"2022","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110748_b0065","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12031183","article-title":"Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study","volume":"12","author":"Bordeau","year":"2023","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/j.radonc.2025.110748_b0075","article-title":"MR-guided stereotactic radiotherapy of infra-diaphragmatic oligometastases: Evaluation of toxicity and dosimetric parameters","volume":"192","author":"van Overeem","year":"2024","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2025.110748_b0085","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"Journal of Biomedical Informatics"},{"key":"10.1016\/j.radonc.2025.110748_b0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.radonc.2025.110748_b0100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12885-019-5362-5","article-title":"The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases","volume":"19","author":"Klement","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2025.110748_b0105","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","article-title":"Stereotactic body radiotherapy for oligometastases","volume":"14","author":"Tree","year":"2013","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2021.12.018","article-title":"An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer","volume":"167","author":"Sheikh","year":"2022","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0115","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.12.288","article-title":"Local Control After Stereotactic Body Radiation Therapy for Liver Tumors","volume":"110","author":"Ohri","year":"2021","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110748_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijrobp.2020.10.039","article-title":"High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview","volume":"110","author":"Grimm","year":"2021","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110748_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109576","article-title":"Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial","volume":"182","author":"Eufemon Cereno","year":"2023","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0130","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.radonc.2021.02.036","article-title":"Liver SBRT with active motion-compensation results in excellent local control for liver oligometastases: An outcome analysis of a pooled multi-platform patient cohort","volume":"158","author":"Stera","year":"2021","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0135","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ijrobp.2015.01.036","article-title":"Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection","volume":"92","author":"Ahmed","year":"2015","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110748_b0140","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13014-021-01813-6","article-title":"Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis","volume":"16","author":"Mayinger","year":"2021","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.radonc.2021.07.026","article-title":"Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy","volume":"163","author":"Chen","year":"2021","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0150","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.rpor.2015.12.004","article-title":"Evaluation of response after SBRT for liver tumors","volume":"22","author":"Tetreau","year":"2017","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.radonc.2025.110748_b0155","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/j.ijrobp.2012.04.041","article-title":"Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases","volume":"84","author":"Howells","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110748_b0160","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00066-016-1013-9","article-title":"MRI morphologic alterations after liver SBRT : Direct dose correlation with intermodal matching","volume":"192","author":"Boda-Heggemann","year":"2016","journal-title":"Strahlentherapie und Onkologie"},{"key":"10.1016\/j.radonc.2025.110748_b0165","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijrobp.2015.01.028","article-title":"Lobulated enhancement evaluation in the follow-up of liver metastases treated by stereotactic body radiation therapy","volume":"92","author":"Jarraya","year":"2015","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110748_b0170","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00261-016-0768-x","article-title":"Stereotactic body radiation therapy of liver tumors: post-treatment appearances and evaluation of treatment response: a pictorial review","volume":"41","author":"Haddad","year":"2016","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.radonc.2025.110748_b0175","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijrobp.2021.11.027","article-title":"A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC)","volume":"113","author":"Lee","year":"2022","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110748_b0180","article-title":"Pseudoprogression Following Liver Stereotactic Body Radiotherapy (SBRT) in a Patient With Oligometastatic Leiomyosarcoma: A Case Report","volume":"16","author":"Aly","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.radonc.2025.110748_b0185","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ijrobp.2016.07.034","article-title":"A Study of Pseudoprogression After Spine Stereotactic Body Radiation Therapy","volume":"96","author":"Bahig","year":"2016","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110748_b0190","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10143-013-0504-8","article-title":"Imaging changes following stereotactic radiosurgery for metastatic intracranial tumors: differentiating pseudoprogression from tumor progression and its effect on clinical practice","volume":"37","author":"Ruzevick","year":"2014","journal-title":"Neurosurgical Review"},{"key":"10.1016\/j.radonc.2025.110748_b0195","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2020.02.008","article-title":"Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer","volume":"146","author":"Jethwa","year":"2020","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijrobp.2020.01.017","article-title":"Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients","volume":"107","author":"Chen","year":"2020","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110748_b0205","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ijrobp.2022.05.033","article-title":"Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial","volume":"114","author":"Baker","year":"2022","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110748_b0210","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ijrobp.2011.08.036","article-title":"Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study","volume":"83","author":"Milano","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110748_b0215","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.lungcan.2023.02.002","article-title":"Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer","volume":"178","author":"Auclin","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2025.110748_b0220","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","article-title":"EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer","volume":"26","author":"Sobrero","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0225","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.radonc.2025.110748_b0230","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"The Lancet Oncology"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402500043X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402500043X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:48:57Z","timestamp":1774417737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402500043X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":46,"alternative-id":["S016781402500043X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110748","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"1-year efficacy results after MR-guided risk-adapted stereotactic radiotherapy of infra-diaphragmatic oligometastases in a multicenter phase II trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110748"}}